



# GLAND PHARMA LIMITED

March 16, 2021

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> floor, Dalal Street  
Mumbai - 400 001  
Scrip Code: 543245

National Stock Exchange of India Limited  
Listing Department  
Exchange Plaza, 5th floor  
Plot no. C-1, Block G, Bandra Kurla Complex  
Bandra (East), Mumbai - 400 051  
Symbol : GLAND (ISIN : INE068V01023)

## **Sub: Intimation under Regulation 30**

Dear Sir/Madam,

Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015; please find attached announcement on “Gland Pharma enters into an Agreement to supply upto 252 million doses of RDIF’s Sputnik V COVID-19 vaccine”.

This is for your information and records.

**Yours truly,**

For Gland Pharma Limited



**Sampath Kumar Pallerlamudi**  
Company Secretary



## **Gland Pharma enters into an Agreement to supply upto 252 million doses of RDIF's Sputnik V COVID-19 vaccine**

**Hyderabad, March 16, 2021:** This is the first of multiple partnerships being explored by Gland Pharma to leverage its manufacturing capacity and capabilities to support global supply of COVID-19 vaccine.

Gland Pharma will be leveraging its manufacturing capabilities for the production of Sputnik V COVID-19 vaccine. The agreement will see Gland Pharma utilising its Drug Substance and Drug Product facilities at its sites in Hyderabad. The production is expected to commence from third quarter of 2021 for estimated delivery starting from fourth quarter of 2021.

Under the terms of the agreement, Gland Pharma will first undertake technology transfer of the drug substance to its manufacturing facilities. After successful technology transfer, Gland Pharma will then undertake manufacturing of drug substance and drug product filling into vials under aseptic conditions. Gland Pharma's expertise in manufacturing of sterile injectable at significant scale will support in establishing a stable supply of COVID-19 vaccine.

\*\*\*\*

**About Gland Pharma (BSE: 543245, NSE: GLAND):** Established in 1978 in Hyderabad, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. It operates primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology and ophthalmic solutions and also enjoys the distinction of having pioneered Heparin technology in India.

**Russian Direct Investment Fund (RDIF)** is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF's management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totalling more than RUB1.9 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia's GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than \$40 bn. Further information can be found at [www.rdif.ru](http://www.rdif.ru)

**Sputnik V** vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the World's first registered vaccine against COVID-19 based on the human adenoviral vector platform.

**The Gamaleya National Research Center for Epidemiology and Microbiology of the Ministry of Health of the Russian Federation** is one of the oldest research centers in Russia, which celebrated its 100th anniversary in 1991. The main focus of the center's research is the fundamental problems in epidemiology, medical and molecular microbiology, and infectious immunology. More information can be found at [www.gamaleya.org](http://www.gamaleya.org)